08:59 AM EDT, 03/12/2026 (MT Newswires) -- Natera ( NTRA ) said Thursday it has commercially launched its Zenith genomics sequencing assay to improve detection of rare diseases.

Zenith genomics offers detection of "typically hard to detect features" like tandem repeat expansions by using long-read sequencing confirmation for diagnostic clarity, according to the company.

Natera ( NTRA ) said genome analysis company MyOme developed the underlying technology supporting Zenith genomics.